Commercial agreement with DESITIN Pharma for ZNEO® Midazolam in Germany

- DESITIN is a leading pharmaceutical company in the field of epilepsy in Germany
- Exclusive Licensing, distribution and promotion agreement
- Pre-marketing payments to CROSSJECT of €2.5m

Dijon, 18 June 2019

CROSSJECT (ISIN: FR0011716265; Ticker: ALCJ), a specialty pharma company that is developing and will soon be marketing a portfolio of combined drugs for use in emergency situations, is announcing the signing of a commercial agreement.

Patrick Alexandre, CEO of Crossject, said: “We are proud to announce a sound commercial agreement for ZNEO® Midazolam in Germany. DESITIN’s focus and leadership position in epilepsy make it a very strong fit for us. With our progress this year, we are confident to reach the goals we have set ourselves, and DESITIN’s trust is a welcomed confirmation for all of us.”

Dr Martin Zentgraf, General Manager of DESITIN, said: “We are very pleased to partner with CROSSJECT to bring to the German medical community, epilepsy sufferers and their families an innovative rescue treatment. Most epilepsy seizures happen outside of a medical setting, and there is a large unmet medical need in this area. Our highly specialised field staff as well as our medical employees provide the physicians with expert and competent assistance. Cooperations with licensors and the successful marketing of products licenced represent a corner stone of DESITIN’s latest developments.”
Epilepsy and DESITIN, a long history

In Germany between 400,000 and 700,000 people are suffering from epilepsy. Since the 1950s DESITIN Arzneimittel GMBH (DESITIN) has been in close contact with the epilepsy medical community, through a team that today includes 33 dedicated employees (medical, marketing and field team members).

With its headquarters in Hamburg, globally 300 employees and €100m of sales, of which over €60m in Germany in the field of neurology, DESITIN has a strong footprint on the German neurology field. It is ranked number 1 in Germany in terms of number of patients treated for epilepsy, and consistently among the top companies for recognition by epilepsy patients.

CROSSJECT develops a rescue kit solution that makes sense

The IntraMuscular injection of Midazolam in case of certain seizures by epileptic patients at risk has become a gold standard. But the impracticality for non-specialists has made this solution rarely used out of hospital. The simplicity of use of Zeneo® (see Intuitive study), and the possibility of an injection without needle in less than 1/10th second will bring new perspectives for the patients.

Key features of the cooperation

The agreement signed today deals mainly with licensing, distribution and promotion, until 10 years after commercial launch, unless certain opt out options are exercised by CROSSJECT or DESITIN, for example if certain minima of sales are not reached or certain development deadlines not met.

A total of €2.5m of premarketing payments will be paid by DESITIN to CROSSJECT: upon signing (for €0.5m), two development milestones expected in early and mid 2020 (for €0.5m each), and

---

1 German epilepsy guidelines S1 “Erster epileptischer Anfall & Epilepsien im Erwachsenenalter 2017”

2 Pre-hospital midazolam for benzodiazepine-treated seizures before and after the Rapid Anticonvulsant Medication Prior to Arrival Trial: A national observational cohort study., Shtull-Leber et al. 2017

3 Human factors study of ZENEØ® (needle-free autoinjector) and comparison of different user instruction formats. Allaert et al. 2018
finally at the approval of Marketing Authorisation (€1m).

DESITIN ran a due-diligence process on, among others, regulatory, pharmaceutical development and technical aspects of CROSSJECT’s development.

CROSSJECT will sell the product to DESITIN at a mid-double digit percentage of DESITIN’s net selling price to wholesalers, with a minimum floor price per unit.

**Business update and outlook**

Since the beginning of 2019:

- Crossject has been authorised to open a pharmaceutical establishment,
- A new funding was received in February (€1.1m),
- The RAPID programme with DGA (French Ministry of Defence) was completed,
- The European Eurostars programme was completed,
- and the process towards the clinical batch production is well advanced.

Crossject is on track for rolling out its model, with the first Market Authorisation filings in 2020 in the Europe and the US.

Contacts:

**Crossject**
Patrick Alexandre
info@crossject.com

**Investor relations**
CM-CIC Market Solutions
Catherine Couanau +33 (0)1 53 48 81 97
catherine.couanau@cmcic.fr

**Press relations**
Buzz & Compagnie
Mélanie Voisard +33 (0)3 80 43 54 89
melanie.voisard@buzzetcompagnie.com
Audrey Lachat +33 (0)3 80 43 54 89
audrey.lachat@buzzetcompagnie.com
About CROSSJECT o www.crossject.com

Crossject (ISIN: FR0011716265, Ticker: ALCJ, LEI: 969500WR7TFN12D85A65) is developing and is soon to market a portfolio of drugs dedicated to emergency situations: epilepsy, overdose, allergic shock, severe migraine and asthma attack. Thanks to its patented needle-free self-injection system, Crossject aims to become the world leader in self-administered emergency drugs. The company has been listed on the Euronext Growth market in Paris since 2014, and benefits from Bpifrance funding.

Translation for information purposes only. In case of discrepancy between the French and English versions of this press release, only the French version should be deemed valid.